{"id":"ctis","name":"Clinical Trials Information System","telecom":[{"system":"url","use":"work","value":"https://euclinicaltrials.eu/"}],"text":{"div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>Données reçues avant modélisation FHIR</h2><ul><li> reglementation_code: REG536 </li><li> precision_reglementation: un essai clinique (CTIS) </li><li> etat: EN_COURS </li><li> organisme_nom: F. Hoffmann-La Roche AG </li><li> organisme_adresse: Grenzacherstrasse 124 </li><li> organisme_code_postal: 4058 </li><li> organisme_pays: Switzerland </li><li> organisme_ville: Basel Town </li><li> contact_nom: Trial Information Support Line-TISL, Switzerland </li><li> contact_prenom: Head of EU </li><li> contact_telephone: 0041616881111 </li><li> contact_courriel: global.rochegenentechtrials@roche.com </li><li> sites: Organisme: Donnée non disponible - Adresse: Avenue Eugene Avinee - Ville: Lille - Titre: Dr. - Nom: Aumar - Prenom: Madeleine - Service: Gastroenterology Hepatology and Nutrition Unit Paediatric clinic, Child Unit </li><li> numero_primaire: 2022-500014-26-00 </li><li> titre: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER </li><li> phase_recherche: Phase III </li><li> domaine_therapeutique: Diseases [C] - Neoplasms [C04] </li><li> pathologies_maladies_rares: Locally-Advanced or Metastatic breast cancer (MBC) </li><li> informations_meddra: 10070575,10065430 </li><li> taille_etude: 21 </li><li> tranches_age: 65+ years,18-64 years </li><li> sexe: Male,Female </li><li> groupes_sujet: Données non disponible </li><li> population_recrutement: Women of child bearing potential not using contraception,Women of child bearing potential using contraception </li><li> date_debut_recrutement: 2022-06-30T00:00:00.000Z </li><li> historique: 2023-03-16:En cours </li><li> dates_avis_favorable_ms_mns: 22.00800.000094-SM-1:2022-11-07, 22.00800.000094-SM-2:2023-04-12 </li><li> pays_concernes: BE,DE,ES,FR,HU,IT,PL,PT </li><li> date_theorique_maximale_autorisation_cpp: 2023-03-15 </li><li> contact_public: Nom: null - Prenom: null Courriel: null Tel: null </li><li> criteres_eligibilite: Titre: null - Type: null,Titre: TEST INCLUSION - Type: INCLUSION,Titre: TEST EXCLUSION - Type: EXCLUSION </li><li> criteres_jugement: Titre: null - Type: null,Titre: TEST PRINCIPAL - Type: PRINCIPAL,Titre: TEST SECONDAIRE - Type: SECONDAIRE </li><li> objectifs: null </li><li> resume: null </li><li> statut_recrutement: Recrutement en attente </li><li> date_fin_recrutement: null </li></ul></div>","status":"extensions"},"resourceType":"Organization"}